Health Care • Biotechnology: Pharmaceutical Preparations
$3.62 ▲ +0.01
(+0.28%)
MKT CAP: $598.2M • VOL: 1.37M
52W L $2 52W H $6
IRWD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $296.2M | $351.4M | $442.7M |
| YoY Revenue Growth % | -15.7% | -20.6% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $98.5M | $93.1M | -$945.4M |
| Operating Margin % | 33.3% | 26.5% | -80.0% |
| Net Income (GAAP) | $24.0M | $880.0K | -$1.03B |
| EBITDA (Normalized) | $98.5M | $93.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $127.0M | $103.5M | $183.4M |
| Capital Expenditures (CapEx) | $34.0K | $142.0K | — |
| Free Cash Flow (FCF) | $127.0M | $103.4M | $183.4M |
| FCF Margin % | 42.9% | 29.4% | 41.4% |
| Return on Invested Capital (ROIC %) | 95.0% | 95.0% | — |
| Cash & Short-Term Equivalents | $215.5M | $88.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$261.8M | -$301.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IRWD.